Bruceine D and afatinib combination inhibits ovarian cancer cells proliferation and migration through DNA damage repair and EGFR pathway

Abstract

Owing to the high rates of relapse and migration, ovarian cancer (OC) has been recognized as the most lethal gynecological malignancy worldwide. The activity of the epidermal growth factor receptor (EGFR) signaling pathway is frequently associated with OC cell proliferation and migration. Despite this knowledge, inhibition of EGFR signaling in OC patients failed to achieve satisfactory therapeutic effects. In this study, we identified that bruceine D (BD) and EGFR inhibitor, afatinib, combination resulted in synergistic anti-OC effects. The results indicated that compared with one of both drugs alone, the combination of BD and afatinib slowed the DNA replication rate, inhibition of cell viability, and proliferation and clone formation. This resulted in cell cycle arrest and cell apoptosis. In addition, the combination of BD and afatinib possessed a stronger ability to inhibit the OC cell adhesion and migration than treatment with BD or afatinib alone. Mechanistically, the combined treatment triggered intense DNA damage, suppressed DNA damage repair, and enhanced the inhibition of the EGFR pathway. These results demonstrated that compared with each pathway inhibition, combined blocking of both DNA damage repair and the EGFR pathway appears to more effective against OC treatment. The results support the potential of BD and afatinib combination as a therapeutic strategy for OC patients.

Keywords

Ovarian neoplasms ErbB receptors DNA damage

Get full access to this article

View all access options for this article.

References

Merlo

Besic

Drmota

, et al. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer. Radiol Oncol 2021; 55:341–346.

Lin

Tanaka

, et al. Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer. Bioengineered 2021; 12:3263-3274.

Lheureux

Gourley

Vergote

, et al. Epithelial ovarian cancer. Lancet 2019; 393:1240–1253.

Agarwal

Kaye

SB.

Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3:502–516.

Meyers

Gerard

Lemaigre

, et al. Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma. Sci Rep 2020; 10: 5241.

Areeb

Stuart

West

, et al. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. Sci Rep 2020; 10: 17768.

Roskoski

Jr.

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res 2019; 139: 395–411.

Lin

Huang

Cho

, et al. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. Theranostics 2020; 10: 10925–10939.

Lafky

Wilken

Baron

, et al. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008; 1785: 232–265.

10.

Tuefferd

Couturier

Penault-Llorca

, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2007; 2: e1138.

11.

Wang

, et al. Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling. Biochem Biophys Res Commun 2022; 637: 348–357.

12.

Brown

Zhang

Westover

, et al. On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation. Clin Cancer Res 2019; 25: 3341–3351.

13.

Modjtahedi

Cho

Michel

, et al. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol 2014; 387: 505–521.

14.

Chavda

Ertas

Walhekar

, et al. Advanced computational methodologies used in the discovery of new natural anticancer compounds. Front Pharmacol 2021; 12: 702611.

15.

Yang

Kong

Ding

, et al. Bruceine D elevates Nrf2 activation to restrain Parkinson’s disease in mice through suppressing oxidative stress and inflammatory response. Biochem Biophys Res Commun 2020; 526: 1013–1020.

16.

Dong

Shi

, et al. Bruceine D inhibits cell proliferation through downregulating LINC01667/MicroRNA-138-5p/Cyclin E1 Axis in Gastric Cancer. Front Pharmacol 2020; 11: 584960.

17.

Cheng

Yuan

, et al. Bruceine D inhibits hepatocellular carcinoma growth by targeting beta-catenin/jagged1 pathways. Cancer Lett 2017; 403:195–205.

18.

Zhang

Lin

Tung

, et al. Bruceine D induces apoptosis in human chronic myeloid leukemia K562 cells via mitochondrial pathway. Am J Cancer Res 2016; 6: 819–826.

19.

Lau

Lin

Liao

, et al. Bruceine D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase. Cancer Lett 2009; 281: 42–52.

20.

Lau

Lin

Leung

PS.

Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. Br J Cancer 2010; 102: 583–593.

21.

Hong

Lin

Wang

, et al. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. J Nanobiotechnology 2019; 17:89.

22.

Chen

Wang

Mohammed Alsayed

, et al. Synthesis and biological evaluation of novel N-substituted benzamides as anti-migration agents for treatment of osteosarcoma. Eur J Med Chem 2021; 214: 113203.

23.

Yang

Pan

Zhang

, et al. Silibinin restores the sensitivity of cisplatin and taxol in A2780-resistant cell and reduces drug-induced hepatotoxicity. Cancer Manag Res 2019; 11:7111-7122.

24.

Chen

Jin

Mei

, et al. The different biological effects of TMPyP4 and cisplatin in the inflammatory microenvironment of osteosarcoma are attributed to G-quadruplex. Cell Prolif 2021; 54: e13101.

25.

Chen

Jin

Shen

, et al. H2O2 enhances the anticancer activity of TMPyP4 by ROS-mediated mitochondrial dysfunction and DNA damage. Med Oncol 2021; 38:59.

26.

Shih

Jang

, et al. Afatinib as first-line treatment in asian patients with EGFR mutation-positive NSCLC: a narrative review of real-world evidence. Adv Ther 2021; 38: 2038–2053.

27.

Niederst

Sequist

Poirier

, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun 2015; 6: 6377.

28.

El-Mais

Fakhoury

Abdellatef

, et al. Human recombinant arginase I [HuArgI (Co)-PEG5000]-induced arginine depletion inhibits ovarian cancer cell adhesion and migration through autophagy-mediated inhibition of RhoA. J Ovarian Res 2021; 14: 13.

29.

Shanbhag

Evans

Mao

, et al. Early neuronal accumulation of DNA double strand breaks in Alzheimer’s disease. Acta Neuropathol Commun 2019; 7: 77.

30.

Hassan

Chitcholtan

Sykes

, et al. Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells. Cancer Lett 2018; 420: 168–181.

31.

Okura

Nishioka

Yamada

, et al. ONO-7475, a Novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer. Clin Cancer Res 2020; 26:2244–2256.

32.

Murphy

Stordal

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat 2011; 14: 177–190.

33.

Gee

Faraahi

McCormick

, et al. DNA damage repair in ovarian cancer: unlocking the heterogeneity. J Ovarian Res 2018; 11: 50.

34.

Zhang

Matsunaga

Lin

, et al. Spontaneous tumor development in bone marrow-rescued DNA-PKcs(3A/3A) mice due to dysfunction of telomere leading strand deprotection. Oncogene 2016; 35: 3909–3918.

35.

Zhou

Zhu

, et al. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage. J Exp Clin Cancer Res 2019; 38: 13.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.42 MB